This invention provides cellular nanovesicles as theranostic agents, combining imaging and therapy into a single system. It involves the creation of plasmonic anucleate cellular nanovesicles derived from red blood cell (RBC) membranes coated with gold nanoparticles. These nanovesicles are designed for use in contrast imaging, drug delivery, and photothermal cancer therapy. The invention also outlines a method for preparing these nanovesicles, highlighting their potential for enhanced imaging due to the high atomic number of gold and efficient cancer cell ablation via photothermal effects. This innovative approach aims to improve the efficacy and specificity of cancer treatments while minimizing side effects.
Figure (1) Photothermal Temperature Rise setup in presence of 808 nm laser.
Current cancer treatment methods, such as chemotherapy and radiation, often result in significant side effects and non-specific targeting of cancerous cells, leading to damage to healthy tissues. Moreover, traditional imaging techniques and therapeutic approaches lack the capability to effectively combine diagnosis and treatment into a single, efficient system. There is a pressing need for innovative solutions that can integrate both diagnostic imaging and targeted therapy, minimizing side effects and enhancing the precision and efficacy of cancer treatment.
- Utilization of red blood cell (RBC) membrane-coated nanovesicles for high biocompatibility and prolonged circulation time.
- Gold nanoparticle coating on RBC nanovesicles for enhanced imaging and photothermal therapy.
- Near-infrared (NIR) responsive properties for deep tissue penetration and minimal damage to non-targeted cells.
- Dual functionality of the nanovesicles as both imaging agents and drug delivery systems.
- Simple and efficient preparation method combining hypotonic treatment and gold coating.
This invention presents red blood cell membrane-derived nanovesicles coated with gold nanoparticles, designed as dual-function theranostic agents for cancer. These biocompatible nanovesicles enable enhanced imaging and targeted photothermal therapy using near-infrared light, allowing deep tissue penetration with minimal side effects. The simple preparation involves hypotonic treatment and gold coating, and the prototype has demonstrated effective photothermal heating under an 808 nm laser, showing promise for improved cancer diagnosis and treatment.
The technology is available for licensing.
2
- Enhanced cancer treatment with reduced side effects and improved patient outcomes.
- Potential reduction in healthcare costs due to the dual functionality of theranostic agents.
- Improvement in the quality of life for cancer patients by providing more targeted and less invasive treatment options.
- Cancer Therapy: Targeted photothermal treatment of cancerous cells
- Medical Imaging: Enhanced contrast imaging for diagnostic purposes
- Drug Delivery: Encapsulation and delivery of therapeutic drugs directly to the tumor site
- Theranostics: Combined diagnostic and therapeutic applications in oncology
Geography of IP
Type of IP
202121012661
426132